{"id":439177,"date":"2025-04-22T00:00:00","date_gmt":"2025-04-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0039-2025-biopharma-multiple-myeloma-unmet-need-unmet-need-third-and-fourth-line-multiple-myeloma-us-eu\/"},"modified":"2026-03-31T10:26:29","modified_gmt":"2026-03-31T10:26:29","slug":"unneon0039-2025-biopharma-multiple-myeloma-unmet-need-unmet-need-third-and-fourth-line-multiple-myeloma-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0039-2025-biopharma-multiple-myeloma-unmet-need-unmet-need-third-and-fourth-line-multiple-myeloma-us-eu\/","title":{"rendered":"Multiple Myeloma &#8211; Unmet Need &#8211; Unmet Need &#8211; Third- and Fourth-Line Multiple Myeloma (US\/EU)"},"content":{"rendered":"<p>The treatment of multiple myeloma is complex, often involving combinations of CD38-blocking monoclonal antibodies (MAbs), immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapy, and corticosteroids across lines of therapy. Due to a lack of treatment options, regimens used to treat third and fourth-line multiple myeloma often include drugs that are also used in earlier lines of treatment. Consequently, third- and fourth-line patients may be refractory to CD38-blocking MAbs, lenalidomide, or bortezomib, highlighting the need for therapies with novel targets. The label expansion of the anti-BCMA CAR T-cell therapies, Bristol Myers Squibb \/ Bluebird Bio\u2019s Abecma and Johnson &#038; Johnson \/ Legend Biotech\u2019s Carvykti, into third- and fourth-lines of therapy has partially addressed this issue. However, the recurring nature of multiple myeloma underscores the need for more efficacious treatments.<\/p>\n<div>\n<p><strong>Questions answered<\/strong><\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW223325880 BCX0 round-bullets\">\n<li>Which attributes most influence physicians\u2019 prescribing decisions in the treatment of third- and fourth-line multiple myeloma?<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW223325880 BCX0 round-bullets\">\n<li>How do hematologist-oncologist rate the performance of current monotherapies and regimens, such as CAR T-cell therapies, on key treatment drivers and goals for this patient population?<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW223325880 BCX0 round-bullets\">\n<li>What are the prevailing areas of unmet need in the treatment of third- and fourth-line multiple myeloma?<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW223325880 BCX0 round-bullets\">\n<li>What trade-offs across different clinical attributes and price are acceptable to surveyed hematologist-oncologists for a hypothetical treatment of third- and fourth-line multiple myeloma?<\/li>\n<\/ul>\n<\/div>\n<p><b>Geography: <\/b>United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> Survey of 60 U.S. and 33 European hematologist-oncologists<\/p>\n<p><strong>Key drugs covered:<\/strong> Darzalex Faspro, Kyprolis, Pomalyst \/ Imnovid, Carvykti, and Abecma<\/p>\n<p><strong>Key feature:<\/strong> Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<div>\n<p><strong>Product description<\/strong><\/p>\n<\/div>\n<div>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW210805749 BCX0 round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW210805749 BCX0 round-bullets\">\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<\/ul>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW210805749 BCX0 round-bullets\">\n<li>Analyze market scenarios for different target product profiles using the TPP Simulator.<\/li>\n<\/ul>\n<\/div>\n","protected":false},"template":"","class_list":["post-439177","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-multiple-myeloma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/439177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/439177\/revisions"}],"predecessor-version":[{"id":575798,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/439177\/revisions\/575798"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=439177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}